NL980008I1 - Gebruik van sertindool voor de behandeling van schizofrenie. - Google Patents

Gebruik van sertindool voor de behandeling van schizofrenie.

Info

Publication number
NL980008I1
NL980008I1 NL980008C NL980008C NL980008I1 NL 980008 I1 NL980008 I1 NL 980008I1 NL 980008 C NL980008 C NL 980008C NL 980008 C NL980008 C NL 980008C NL 980008 I1 NL980008 I1 NL 980008I1
Authority
NL
Netherlands
Prior art keywords
sertindole
treat schizophrenia
dopamine neurones
neurones
imidazolidinon
Prior art date
Application number
NL980008C
Other languages
English (en)
Dutch (nl)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10654774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL980008(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NL980008I1 publication Critical patent/NL980008I1/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
NL980008C 1989-04-11 1998-02-18 Gebruik van sertindool voor de behandeling van schizofrenie. NL980008I1 (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898908085A GB8908085D0 (en) 1989-04-11 1989-04-11 New therapeutic use

Publications (1)

Publication Number Publication Date
NL980008I1 true NL980008I1 (nl) 1998-05-06

Family

ID=10654774

Family Applications (1)

Application Number Title Priority Date Filing Date
NL980008C NL980008I1 (nl) 1989-04-11 1998-02-18 Gebruik van sertindool voor de behandeling van schizofrenie.

Country Status (17)

Country Link
US (1) US5112838A (enExample)
EP (1) EP0392959B1 (enExample)
JP (1) JP2775191B2 (enExample)
KR (1) KR920008703B1 (enExample)
AT (1) ATE157005T1 (enExample)
AU (1) AU621735B2 (enExample)
CA (1) CA2014208C (enExample)
CY (1) CY2082B1 (enExample)
DE (2) DE19875011I2 (enExample)
DK (1) DK0392959T3 (enExample)
GB (1) GB8908085D0 (enExample)
IE (1) IE81157B1 (enExample)
IL (1) IL94021A (enExample)
NL (1) NL980008I1 (enExample)
NZ (2) NZ243765A (enExample)
SG (1) SG48234A1 (enExample)
ZA (1) ZA902785B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238945A (en) * 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
DK238190D0 (da) * 1990-10-03 1990-10-03 Lundbeck & Co As H Depotderivater
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
DK206591D0 (da) * 1991-12-23 1991-12-23 Lundbeck & Co As H Behandling af psykoser
DK8492D0 (da) * 1992-01-23 1992-01-23 Lundbeck & Co As H Behandling af psykoser
DK123493D0 (da) * 1993-11-01 1993-11-01 Lundbeck & Co As H Compounds
EP0906104A4 (en) * 1996-03-25 2003-12-10 Lilly Co Eli PAIN TREATMENT PROCESS
ZA973433B (en) * 1996-04-24 1997-12-10 Shionogi & Co A sertindole-containing preparation and a method for producing the same.
DK1026950T3 (da) * 1997-10-27 2006-06-26 Univ California Behandling af skizofreni med ampakiner og neuroleptika
GB9805716D0 (en) * 1998-03-17 1998-05-13 Merck Sharp & Dohme Therapeutic agents
US6489341B1 (en) 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
DE60239634D1 (de) * 2001-12-10 2011-05-12 Novartis Ag Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen
MXPA04009365A (es) * 2002-03-27 2005-01-25 Lundbeck & Co As H Metodo para la manufactura de sertindol.
CA2525366A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
MXPA06013163A (es) * 2004-05-11 2007-02-13 Pfizer Prod Inc Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
DE602005008084D1 (de) * 2004-08-24 2008-08-21 Janssen Pharmaceutica Nv Als antikonvulsive mittel geeignete neue benzokondensierte heteroarylsulfamidderivate
KR20080012360A (ko) * 2005-05-20 2008-02-11 얀센 파마슈티카 엔.브이. 설파미드 유도체의 제조 방법
US20070212412A1 (en) * 2005-09-08 2007-09-13 H. Lundbeck A/S Stable solid formulation of sertindole
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
EA200870556A1 (ru) * 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. Комбинированная терапия в лечении эпилепсии и родственных расстройств
TW200821296A (en) * 2006-06-01 2008-05-16 Lundbeck & Co As H Use of sertindole for the preventive treatment of suicidal behaviour
EP2041304B1 (en) * 2006-06-12 2011-09-07 Hadasit Medical Research Services & Development Limited Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
PL2083811T3 (pl) 2006-11-22 2017-05-31 Clinical Research Associates, Llc Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
WO2008106144A2 (en) * 2007-02-28 2008-09-04 Nupathe Inc. Implants for the treatment of psychiatric states
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
EP2288345B1 (en) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psycho-pharmaceuticals
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
CA2727573A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8252801B1 (en) 2009-06-03 2012-08-28 Abbott Laboratories Treatment of schizophrenia and related disorders
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359468A (en) * 1981-02-25 1982-11-16 Boehringer Ingelheim Ltd. Antiallergic N-[4-(indolyl)-piperidino-alkyl]-benzimidazolones
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
US4742057A (en) * 1985-12-05 1988-05-03 Fujisawa Pharmaceutical Co., Ltd. Antiallergic thiazole compounds
ZA891901B (en) * 1988-03-17 1989-11-29 Merrell Dow Pharma Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy

Also Published As

Publication number Publication date
EP0392959A3 (en) 1992-05-06
IE901051L (en) 1990-10-11
IE81157B1 (en) 2000-05-03
AU621735B2 (en) 1992-03-19
NZ243765A (en) 1997-09-22
JP2775191B2 (ja) 1998-07-16
US5112838A (en) 1992-05-12
DK0392959T3 (da) 1999-03-29
AU5303790A (en) 1990-10-18
EP0392959B1 (en) 1997-08-20
CA2014208C (en) 1996-03-19
KR900015730A (ko) 1990-11-10
GB8908085D0 (en) 1989-05-24
ZA902785B (en) 1991-06-26
DE69031290D1 (de) 1997-09-25
CY2082B1 (en) 1998-10-16
IL94021A (en) 1994-01-25
CA2014208A1 (en) 1990-10-11
JPH02290872A (ja) 1990-11-30
DE19875011I2 (de) 2004-07-01
DE69031290T2 (de) 1998-01-02
NZ233179A (en) 1996-12-20
IL94021A0 (enExample) 1991-01-31
HK1002825A1 (en) 1998-09-18
KR920008703B1 (ko) 1992-10-08
EP0392959A2 (en) 1990-10-17
ATE157005T1 (de) 1997-09-15
SG48234A1 (en) 1998-04-17

Similar Documents

Publication Publication Date Title
NL980008I1 (nl) Gebruik van sertindool voor de behandeling van schizofrenie.
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
DE69225421D1 (de) Sumatriptan enthaltende Arzneimittel
SE8804629D0 (sv) New therapeutically active compounds
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
DE69732170D1 (de) Formulierung mit verzögerter Freisetzung enthaltend Kollagen und Glykosaminoglykan
NL970006I1 (nl) Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.
NO178338C (no) Analogifremgangsmåte for fremstilling av en terapeutisk aktiv benzimidazolforbindelse samt mellomprodukt
NO167204C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive diacylderivater av 4-(trialkylbenzyl)-piperazinylforbindelser.
NO178336C (no) Analogifremgangsmåte for fremstilling av en terapeutisk aktiv benzimidazolforbindelse og mellomprodukter
NO155137C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive derivater av 2-(4-piperidyl)-1-(4-kinolyl)-etanon.
PT790236E (pt) Pro-farmacos de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil-6-cloro-1,3-di-hidro-2h-indol-2-ona
DE3778642D1 (de) Therapeutikum zur behandlung von magengeschwueren.
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
NO893256L (no) Fremgangsmaate for fremstilling av furyltiazolderivater.
WO1994016705A3 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders
IT8919216A0 (it) Dispositivo per la cura chirurgica dell'astigmatismo.
NO882279D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive endo-bicyklo (2,2,1) heptyl-adenosin-derivater.